← All trials
NCT07226076
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 28, 2025
- Primary completion
- Nov 28, 2026
- Completion date
- Dec 15, 2026
- First posted
- Nov 7, 2025
- Last posted
- Nov 12, 2025
- Enrollment
- 162
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Medical University of South CarolinaLead sponsor
- Medical University of South CarolinaOfficial
- Medical University of South CarolinaSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.